342 related articles for article (PubMed ID: 24560935)
1. Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde?
Cruz-Monteagudo M; Medina-Franco JL; Pérez-Castillo Y; Nicolotti O; Cordeiro MN; Borges F
Drug Discov Today; 2014 Aug; 19(8):1069-80. PubMed ID: 24560935
[TBL] [Abstract][Full Text] [Related]
2. Activity cliffs: facts or artifacts?
Medina-Franco JL
Chem Biol Drug Des; 2013 May; 81(5):553-6. PubMed ID: 23375049
[TBL] [Abstract][Full Text] [Related]
3. Duality of activity cliffs in drug discovery.
Bajorath J
Expert Opin Drug Discov; 2019 Jun; 14(6):517-520. PubMed ID: 30882260
[No Abstract] [Full Text] [Related]
4. From activity cliffs to activity ridges: informative data structures for SAR analysis.
Vogt M; Huang Y; Bajorath J
J Chem Inf Model; 2011 Aug; 51(8):1848-56. PubMed ID: 21761918
[TBL] [Abstract][Full Text] [Related]
5. Do medicinal chemists learn from activity cliffs? A systematic evaluation of cliff progression in evolving compound data sets.
Dimova D; Heikamp K; Stumpfe D; Bajorath J
J Med Chem; 2013 Apr; 56(8):3339-45. PubMed ID: 23527828
[TBL] [Abstract][Full Text] [Related]
6. From activity cliffs to target-specific scoring models and pharmacophore hypotheses.
Seebeck B; Wagener M; Rarey M
ChemMedChem; 2011 Sep; 6(9):1630-9, 1533. PubMed ID: 21751401
[TBL] [Abstract][Full Text] [Related]
7. Prediction of individual compounds forming activity cliffs using emerging chemical patterns.
Namasivayam V; Iyer P; Bajorath J
J Chem Inf Model; 2013 Dec; 53(12):3131-9. PubMed ID: 24304008
[TBL] [Abstract][Full Text] [Related]
8. Integrating medicinal chemistry, organic/combinatorial chemistry, and computational chemistry for the discovery of selective estrogen receptor modulators with Forecaster, a novel platform for drug discovery.
Therrien E; Englebienne P; Arrowsmith AG; Mendoza-Sanchez R; Corbeil CR; Weill N; Campagna-Slater V; Moitessier N
J Chem Inf Model; 2012 Jan; 52(1):210-24. PubMed ID: 22133077
[TBL] [Abstract][Full Text] [Related]
9. Modeling of activity landscapes for drug discovery.
Bajorath J
Expert Opin Drug Discov; 2012 Jun; 7(6):463-73. PubMed ID: 22475223
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in understanding activity cliffs and their utility in medicinal chemistry.
Stumpfe D; Hu Y; Dimova D; Bajorath J
J Med Chem; 2014 Jan; 57(1):18-28. PubMed ID: 23981118
[TBL] [Abstract][Full Text] [Related]
11. Exploring activity cliffs in medicinal chemistry.
Stumpfe D; Bajorath J
J Med Chem; 2012 Apr; 55(7):2932-42. PubMed ID: 22236250
[No Abstract] [Full Text] [Related]
12. Searching for coordinated activity cliffs using particle swarm optimization.
Namasivayam V; Bajorath J
J Chem Inf Model; 2012 Apr; 52(4):927-34. PubMed ID: 22404190
[TBL] [Abstract][Full Text] [Related]
13. MMP-Cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs.
Hu X; Hu Y; Vogt M; Stumpfe D; Bajorath J
J Chem Inf Model; 2012 May; 52(5):1138-45. PubMed ID: 22489665
[TBL] [Abstract][Full Text] [Related]
14. Evolution of the activity cliff concept for structure-activity relationship analysis and drug discovery.
Bajorath J
Future Med Chem; 2014 Sep; 6(14):1545-9. PubMed ID: 25367389
[No Abstract] [Full Text] [Related]
15. Exposing the Limitations of Molecular Machine Learning with Activity Cliffs.
van Tilborg D; Alenicheva A; Grisoni F
J Chem Inf Model; 2022 Dec; 62(23):5938-5951. PubMed ID: 36456532
[TBL] [Abstract][Full Text] [Related]
16. Extending the activity cliff concept: structural categorization of activity cliffs and systematic identification of different types of cliffs in the ChEMBL database.
Hu Y; Bajorath J
J Chem Inf Model; 2012 Jul; 52(7):1806-11. PubMed ID: 22758389
[TBL] [Abstract][Full Text] [Related]
17. Breaking the data barrier in computational medicinal chemistry.
Schneider G
Future Med Chem; 2014 Mar; 6(3):245-6. PubMed ID: 24575959
[No Abstract] [Full Text] [Related]
18. Medicinal chemistry matters - a call for discipline in our discipline.
Johnstone C
Drug Discov Today; 2012 Jun; 17(11-12):538-43. PubMed ID: 22301070
[TBL] [Abstract][Full Text] [Related]
19. Computational medicinal chemistry in fragment-based drug discovery: what, how and when.
Rabal O; Urbano-Cuadrado M; Oyarzabal J
Future Med Chem; 2011 Jan; 3(1):95-134. PubMed ID: 21428828
[TBL] [Abstract][Full Text] [Related]
20. Chemical landscape analysis with the OpenTox framework.
Jeliazkova N; Jeliazkov V
Curr Top Med Chem; 2012; 12(18):1987-2001. PubMed ID: 23110534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
